Women with HER2-positive breast cancer who receive HER2-targeted therapies during pregnancy face a higher risk for severe adverse outcomes to their fetus or newborn, new research indicates.
Roivant Sciences said on Monday its experimental drug to treat systemic lupus erythematosus failed to reduce symptoms of the autoimmune disease in a mid-stage study.
In spring 2024, the ACR is expected to release guidelines to help inform the screening, monitoring, and treatment of interstitial lung disease (ILD) in people with SARDs.